首页> 外文期刊>Cancer biology & therapy >Oligomannurarate sulfate, a novel antimitotic agent, exerts anti-cancer activity by binding to tubulin on novel site.
【24h】

Oligomannurarate sulfate, a novel antimitotic agent, exerts anti-cancer activity by binding to tubulin on novel site.

机译:寡甘露酸硫酸盐,一种新型抗有丝分裂剂,通过与新位点的微管蛋白结合而发挥抗癌活性。

获取原文
获取原文并翻译 | 示例
       

摘要

Tubulin-binding agents have received considerable interest as potential anti-cancer drugs. These compounds interfere with tubulin dynamics and microtubule organization and thereby induce cell growth arrest at G(2)/M phase, and eventually lead to apoptotic cell death. Herein, we report that sulfated oligosaccharide JG3 was effective at inhibiting viability of cancer cells, and suppressing tumor growth in vivo. Our studies showed that JG3 significantly arrested cell cycle at G(2)/M phase and led cancer cells to apoptotic death. Consistent with this, tubulin was identified as a binding protein of JG3 using affinity chromatography and liquid chromatography-tandem mass spectrometry (LC-MS/MS). The interaction between JG3 and tubulin was characterized by surface plasmon resonance (SPR) analysis. Furthermore, it was demonstrated both at cellular level and in cell free system that JG3 potently prevented tubulin polymerization, thereby demolished microtubule organization in cancer cells. The underlying mechanism lies in its binding to tubulin on a unique site distinct from other conventional binding sites. All these suggest that JG3 is a novel antimitotic reagent, and this might shed new light on the understanding of anti-cancer activities and mechanisms of novel antimitotic reagents, and help develop new antimitotic agents in cancer therapy.
机译:微管蛋白结合剂作为潜在的抗癌药已引起了广泛的关注。这些化合物干扰微管蛋白动力学和微管组织,从而诱导细胞生长停滞在G(2)/ M期,并最终导致凋亡性细胞死亡。在此,我们报道了硫酸化的寡糖JG3在抑制癌细胞的生存力和体内抑制肿瘤生长方面是有效的。我们的研究表明,JG3可以在G(2)/ M期显着阻止细胞周期,并导致癌细胞凋亡性死亡。与此相一致,使用亲和色谱和液相色谱-串联质谱法(LC-MS / MS)将微管蛋白鉴定为JG3的结合蛋白。 JG3和微管蛋白之间的相互作用通过表面等离振子共振(SPR)分析来表征。此外,在细胞水平和无细胞系统中均证明JG3有效地阻止微管蛋白聚合,从而破坏了癌细胞中的微管组织。潜在的机制在于其与微管蛋白在不同于其他常规结合位点的独特位点上的结合。所有这些表明,JG3是一种新型的抗有丝分裂剂,这可能为了解抗癌活性和新型抗有丝分裂剂的机理提供新的思路,并有助于开发癌症治疗中的新型抗有丝分裂剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号